Clinical
Ortho CEO leads massive turnaround
March 07, 2018When Ortho Clinical Diagnostics lived under the roof of Johnson & Johnson, it had the luxury of focusing on its product and service mix — and not a whole lot else.
Five things for pharma marketers to know: Friday, December 8, 2017
December 08, 2017FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
Five things for pharma marketers to know: Thursday, November 16, 2017
November 16, 2017Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial
Five things for pharma marketers to know: Monday, November 13, 2017
November 13, 2017Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
Can marketing techniques save clinical trials?
September 05, 2017No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
Five things for pharma marketers to know: Monday, July 31, 2017
July 31, 2017FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Five things for pharma marketers to know: Thursday, July 6, 2017
July 06, 2017The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
Five things for pharma marketers to know: Monday, April 10, 2017
April 10, 2017Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Five things for pharma marketers to know: Monday, March 20, 2017
March 20, 2017Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain
March 17, 2017Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
When It Comes to the FDA, Does It All Come Down to Money?
March 06, 2017In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Five things for pharma marketers to know: Wednesday, February 15, 2017
February 15, 2017Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Five things for pharma marketers to know: Tuesday, February 7, 2017
February 07, 2017Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
For statin-intolerant patients, what's next?
January 10, 2017Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials
December 07, 2016The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.
Five things for pharma marketers to know: Tuesday, November 8, 2016
November 08, 2016FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
Interview | Jeanne Martel, ClinicalMind
October 11, 2016Jeanne Martel, president and partner at ClinicalMind, highlights her company's vision and role in communication and technology with MM&M's Jaimy Lee. This video was sponsored by ClinicalMind.
Five things for pharma marketers to know: Tuesday, December 8, 2015
December 08, 2015Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma
Five things for pharma marketers to know: Tuesday, November 10, 2015
November 10, 2015Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug
Five things for pharma marketers to know: Tuesday, November 3, 2015
November 03, 2015GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development
Five things for pharma marketers to know: Tuesday, October 20, 2015
October 20, 2015Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands
Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead
August 25, 2015Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.
Five things for pharma marketers to know: Wednesday, August 19
August 19, 2015Sprout's controversial sexual-desire drug receives FDA approval; prescription-drug coverage impacts cash sales at Walmart; Mylan warned about manufacturing violations
Five things for pharma marketers to know: Tuesday, August 18
August 18, 2015Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children
Five things for pharma marketers to know: Tuesday, August 11
August 11, 2015"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling
Merck files Keytruda for lung cancer, eyes first-line niche
April 20, 2015Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.
Practice Fusion partners with AstraZeneca
April 13, 2015Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.
Five things for pharma marketers to know: Monday, March 16
March 16, 2015New data suggest Amgen's PCSK9 may reduce risks of heart attacks, Salix bidding is war too rich for Endo's blood, Actavis bipolar drug use is expanded to 10- to 17-year-olds.
Five things for pharma marketers to know: Monday, March 9
March 09, 2015Novartis CEO says cost cutting is looming; Novo Nordisk presents new Saxenda weight-loss data; FDA approves Astellas Pharma's antifungal drug.
Eisai and Merck make cancer research pact
March 05, 2015The drugmakers will explore combinations of Merck's Keytruda and Eisai's Lenvima and Halaven to treat certain cancers.
